EMA Authorised: Zydelig (Idelalisib) — Gilead Sciences Ireland UC

View source ↗

Summary

EMA authorised Zydelig (idelalisib) for certain non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Zydelig (idelalisib)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell. MAH: Gilead Sciences Ireland UC. Decision date: 20/06/2024